LUND, SE / ACCESS Newswire / February 19, 2025 / Cantargia AB (publ) ("Cantargia") today announced that members of Cantargia's management will participate in one-on-one meetings at the Leerink ...

Fintel reports that on February 18, 2025, Leerink Partners initiated coverage of aTyr Pharma (NasdaqCM:ATYR) with a ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly ...

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, exclusively focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Stock analysts at Leerink Partnrs increased their Q1 2025 earnings per share estimates for DexCom in a research report issued ...

Leerink Partnrs issued their Q1 2025 EPS estimates for Blueprint Medicines in a research note issued on Thursday, February ...

Incorporated (NYSE: ELAN) shares have reached a 52-week low, dipping to $11.11, as the company faces a tumultuous market environment. With a market capitalization of $5.55 billion and a beta of 1.42, ...